| dc.contributor.author | Kim, Min Seo et al. | |
| dc.date.accessioned | 2020-06-15T19:02:26Z | |
| dc.date.available | 2020-06-15T19:02:26Z | |
| dc.date.issued | 2020-06-14 | |
| dc.identifier.uri | https://doi.org/10.1101/2020.05.13.20094193 | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/1750 | |
| dc.description.abstract | The authors have withdrawn this manuscript because of the controversy about hydroxychloroquine and potential changes in results after peer-review, the authors intend to share their results in formal publication. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author. | en_US |
| dc.language | English | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | Coronavirus | en_US |
| dc.subject | Hydroxychloroquine | en_US |
| dc.subject | Lopinavir | en_US |
| dc.subject | Ritonavir | en_US |
| dc.subject | Anti-Bacterial Agents | en_US |
| dc.subject | Coronavirus Infections | en_US |
| dc.subject | Drug Therapy | en_US |
| dc.title | Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea | en_US |
| eihealth.country | Global (WHO/OMS) | en_US |
| eihealth.category | Candidate therapeutics RD | en_US |
| eihealth.type | Published Article | en_US |
| eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
| dc.relation.ispartofjournal | medRxiv | en_US |
